Just wanted to comment on this:
^the Tavistock initiated in 2011, but that hadn't completed the peer review process and so wasn't ready.
You'd have thought, wouldn't you, that the Tavistock, knowing this case was pending, would have pulled out all the stops to get it completed in time?^
I know the judgement was quite incredulous ability how long this study is taking, but I'm actually sympathetic to the Tavistock on this point.
In the judgement, the study is described like this:
Until 2011 PBs were only available at GIDS for those aged 16 or older. In 2011 PBs started to be prescribed for those aged 12-15 and in mid-puberty. This was first done between 2011-14 at University College London Hospital (UCLH) under an approved research study known as the Early Intervention Study. The Study took an uncontrolled treatment cohort of 12-15 year olds with established and persistent GD in England. The Study recruited children for 3 years, but there was then a period until February 2019 when the last cohort member began the next stage of therapy (cross-sex hormones).
It makes sense that getting the data is really slow. It took them 3 years to recruit enough participants. They then have to wait up to 4 years per participant to get outcome data about progression to cross sex hormones. That meant that they didn't have all the date ready to analyse until February 2019.
It is reasonable to assume say 6 months of data analysis and paper writing, then at least another 4 - 6 months of revisions. More if the paper was rejected from the first journal they chose and had to be completely reformatted for submission to a different one. Academic publishing moves at a glacial pace, even when not in a pandemic.
So the fact that the study is not published yet is not surprising to me.
What is surprising is that they wouldn't submit either the draft or some of the raw data for the court to see.